{"id":"zirconium-cyclosilicate","safety":{"commonSideEffects":[{"rate":"null","effect":"Constipation"},{"rate":"null","effect":"Nausea"},{"rate":"null","effect":"Abdominal discomfort"}]},"_chembl":null,"_dailymed":{"setId":"8833d6e6-33ab-4ea9-b78f-3ec30a904ef8","title":"LOKELMA (SODIUM ZIRCONIUM CYCLOSILICATE) POWDER, FOR SUSPENSION [A-S MEDICATION SOLUTIONS]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The drug is a microporous, inorganic compound that selectively binds potassium ions in the colon through ion-exchange mechanisms. By binding potassium in the GI tract, it prevents reabsorption and increases elimination via feces, thereby reducing serum potassium levels without systemic absorption.","oneSentence":"Zirconium cyclosilicate is a non-absorbed potassium binder that traps potassium in the gastrointestinal tract and increases fecal potassium excretion.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:55:07.466Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hyperkalemia in adults"}]},"trialDetails":[{"nctId":"NCT03813407","phase":"PHASE3","title":"An Open-label Study to Assess Safety and Efficacy of SZC in Paediatric Patients With Hyperkalaemia","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2019-04-02","conditions":"Hyperkalaemia","enrollment":140},{"nctId":"NCT06578078","phase":"PHASE3","title":"A Clinical Trial to Define the Best Strategy for the Management of Heart Failure in Elderly Patients","status":"RECRUITING","sponsor":"Fundación para la Investigación del Hospital Clínico de Valencia","startDate":"2024-10-03","conditions":"Heart Failure, Chronic Kidney Diseases","enrollment":94},{"nctId":"NCT07029503","phase":"PHASE2","title":"Swedish Cardiac And Renal Failure Study-1","status":"RECRUITING","sponsor":"Karolinska Institutet","startDate":"2026-02","conditions":"HFrEF - Heart Failure With Reduced Ejection Fraction, Chronic Kidney Disease","enrollment":40},{"nctId":"NCT05056727","phase":"PHASE3","title":"A Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Participants With CKD and Hyperkalaemia or at Risk of Hyperkalaemia","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2021-09-30","conditions":"Renal Insufficiency, Chronic, Hyperkalemia","enrollment":1112},{"nctId":"NCT06185660","phase":"","title":"A National, Multicenter, Prospective, Observational Study to Assess Patient Characteristics, Treatment Algorithms and Disease Management of Hyperkalaemia Patients With Chronic Kidney Disease or Under Dialysis or With Heart Failure, Treated With Sodium Zirconium Cyclosilicate in Greece","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2024-02-09","conditions":"Hyperkalaemia","enrollment":125},{"nctId":"NCT05347693","phase":"PHASE4","title":"Continuing Sodium Zirconium Cyclosilicate (SZC) After Discharge Study","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2022-03-24","conditions":"Hyperkalaemia, Chronic Kidney Disease","enrollment":186},{"nctId":"NCT04585542","phase":"PHASE4","title":"Comparison of Potassium Binders in the ER","status":"TERMINATED","sponsor":"University of California, Irvine","startDate":"2020-10-20","conditions":"Acute Hyperkalemia, Oral Potassium Binders","enrollment":37},{"nctId":"NCT04676646","phase":"PHASE4","title":"Study to Assess Efficacy and Safety of SZC for the Management of High Potassium in Patients With Symptomatic HFrEF Receiving Spironolactone","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2021-03-08","conditions":"Hyperkalaemia, Heart Failure With Reduced Ejection Fraction","enrollment":366},{"nctId":"NCT04789239","phase":"PHASE2","title":"OPtimizing Aldosterone Receptor Antagonist Therapy by Sodium Zirconium Cyclosilicate in Heart Failure","status":"ACTIVE_NOT_RECRUITING","sponsor":"Michael Fu","startDate":"2021-09-01","conditions":"Heart Failure, Hyperkalemia","enrollment":110},{"nctId":"NCT04847232","phase":"PHASE3","title":"Effect of Sodium Zirconium Cyclosilicate on Arrythmia-related Cardiovascular Outcomes in Participants on Chronic Hemodialysis With Recurrent Hyperkalemia (DIALIZE-Outcomes)","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2021-04-30","conditions":"Hyperkalemia","enrollment":2690},{"nctId":"NCT04983979","phase":"PHASE2","title":"The ORTIZ Study: Optimising RASi Therapy With SZC","status":"TERMINATED","sponsor":"Barts & The London NHS Trust","startDate":"2022-06-17","conditions":"CKD, Diabetes Mellitus, Type 2, Hyperkalemia","enrollment":18},{"nctId":"NCT06635499","phase":"","title":"VITALIZE.Use and Effectiveness of Sodium Zirconium Cyclosilicate (LokelmaTM) in the Real-world Setting in Spain","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2024-11-13","conditions":"Hyperkalaemia","enrollment":232},{"nctId":"NCT03528681","phase":"PHASE3","title":"A Study to Investigate the Safety and Efficacy of ZS in Patients With Hyperkalemia.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2021-05-06","conditions":"Hyperkalemia","enrollment":270},{"nctId":"NCT06365684","phase":"PHASE4","title":"Sodium Zirconium Cyclosilicate to Allow Liberal Fruit and Vegetable Intake for Patients With CKD Stage 3b and 4","status":"RECRUITING","sponsor":"Leiden University Medical Center","startDate":"2024-04-29","conditions":"Hyperkalemia, Diet Modification, Chronic Kidney Disease","enrollment":16},{"nctId":"NCT06029179","phase":"NA","title":"SZC Versus SPS for Treatment of Hyperkalemia in Hemodialysis Patients","status":"COMPLETED","sponsor":"Alexandria University","startDate":"2024-01-15","conditions":"Hyperkalemia","enrollment":120},{"nctId":"NCT06736184","phase":"PHASE4","title":"The Cardioprotective Effects of Improving Potassium Variability in Maintenance Hemodialysis Patients","status":"NOT_YET_RECRUITING","sponsor":"Qianfoshan Hospital","startDate":"2025-03-01","conditions":"Chronic Kidney Disease on Hemodialysis, Hypokalemia, Hyperkalemia","enrollment":100},{"nctId":"NCT05271266","phase":"","title":"A Multicenter, Prospective, Non-interventional Cohort Study to Evaluate the Safety and Treatment Pattern of Sodium Zirconium Cyclosilicate for Hyperkalaemia Management in Real World Practice in China","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2022-03-22","conditions":"Hyperkalaemia","enrollment":1000},{"nctId":"NCT06578533","phase":"PHASE3","title":"Keeping RAASi Treatment With Optimal Potassium Control","status":"RECRUITING","sponsor":"Fundación para la Investigación del Hospital Clínico de Valencia","startDate":"2022-09-30","conditions":"Chronic Kidney Diseases","enrollment":78},{"nctId":"NCT04788641","phase":"PHASE1","title":"Study to Assess the Effect of Sodium Zirconium Cyclosilicate on the Pharmacokinetics of Tacrolimus and Cyclosporin in Healthy Subjects","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2021-03-30","conditions":"Hyperkalaemia","enrollment":62},{"nctId":"NCT04566653","phase":"","title":"Patient Palatability and Preference of 3 Potassium Binders in Patients With Chronic Kidney Disease and Hyperkalaemia","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2020-10-23","conditions":"Chronic Kidney Disease + Hyperkalaemia +/- Heart Failure","enrollment":147},{"nctId":"NCT04727528","phase":"PHASE3","title":"Study of the Effect of SZC on Serum Potassium and Serum Bicarbonate in Patients With Hyperkalemia and Metabolic Acidosis Associated With Chronic Kidney Disease","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2021-03-22","conditions":"Hyperkalaemia, Metabolic Acidosis, Chronic Kidney Disease","enrollment":39},{"nctId":"NCT04207203","phase":"NA","title":"Healthy Diet Rich in Potassium to Chronic Kidney Disease With Sodium Zirconium Cyclosilicate: A Feasibility Study","status":"COMPLETED","sponsor":"Karolinska Institutet","startDate":"2020-11-03","conditions":"Chronic Kidney Disease stage4, Chronic Kidney Disease Stage 5, Hyperkalemia","enrollment":26},{"nctId":"NCT05004363","phase":"PHASE3","title":"Lokelma for RAAS Maximisation in CKD & Heart Failure.","status":"UNKNOWN","sponsor":"St George's, University of London","startDate":"2022-01-19","conditions":"Chronic Kidney Diseases, Heart Failure With Reduced Ejection Fraction, Hyperkalemia","enrollment":130},{"nctId":"NCT04217590","phase":"PHASE3","title":"Reduce Incidence of Pre-Dialysis Hyperkalaemia With Sodium Zirconium Cyclosilicate in Chinese Subjects","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2020-11-16","conditions":"Hyperkalemia","enrollment":134},{"nctId":"NCT04997161","phase":"PHASE4","title":"Study of SZC and Enhanced Nutrition Advice Compared to SoC in Dialysis Patients With Hyperkalaemia","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2021-08-17","conditions":"Hyperkalaemia","enrollment":3},{"nctId":"NCT05382988","phase":"PHASE3","title":"Sodium Zirconium Cyclosilicate Lowers Hyperkalemia After Parathyroidectomy","status":"COMPLETED","sponsor":"Guangdong Provincial People's Hospital","startDate":"2016-11","conditions":"Sodium Zirconium Cyclosilicate, Hyperkalemia, Hyperparathyroidism, Secondary","enrollment":62},{"nctId":"NCT03532009","phase":"PHASE2","title":"Potassium Reduction Initiative to Optimize RAAS Inhibition Therapy With Sodium Zirconium Cyclosilicate in Heart Failure","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2018-06-26","conditions":"Heart Failure","enrollment":182},{"nctId":"NCT04727840","phase":"PHASE1","title":"Potassium Binder in CKD Patients (With Hyperkalemia) (DiPo Trial)","status":"UNKNOWN","sponsor":"Brigham and Women's Hospital","startDate":"2021-03-15","conditions":"Chronic Kidney Diseases, Hyperkalemia","enrollment":20},{"nctId":"NCT02875834","phase":"PHASE3","title":"A Study to Investigate the Safety and Efficacy of ZS in Patients With Hyperkalemia","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2017-03-03","conditions":"Hyperkalemia","enrollment":267},{"nctId":"NCT03172702","phase":"PHASE3","title":"Open-label Safety of Sodium Zirconium Cyclosilicate for up to 12 Months in Japanese Subjects With Hyperkalemia","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2017-09-04","conditions":"Hyperkalemia","enrollment":150},{"nctId":"NCT03303521","phase":"PHASE3","title":"A Study to Test Whether ZS (Sodium Zirconium Cyclosilicate) Can Reduce the Incidence of Increased Blood Potassium Levels Among Dialized Patients.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2017-12-14","conditions":"Hyperkalemia","enrollment":196},{"nctId":"NCT03337477","phase":"PHASE2","title":"A Study to Evaluate a Potassium Normalization Treatment Regimen Including Sodium Zirconium Cyclosilicate (ZS) Among Patients With S-K ≥5.8","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2018-02-13","conditions":"Hyperkalemia","enrollment":70},{"nctId":"NCT04063930","phase":"PHASE4","title":"The Effect of Sodium Zirconium Cyclosilicate on Albuminuria in Patients With Type 2 Diabetes and Hyperkalemia","status":"UNKNOWN","sponsor":"Steno Diabetes Center Copenhagen","startDate":"2019-10","conditions":"Type 2 Diabetes Mellitus With Kidney Complications","enrollment":20},{"nctId":"NCT03127644","phase":"PHASE2, PHASE3","title":"ZS Ph2/3 Dose-response Study in Japan","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2017-06-14","conditions":"Hyperkalemia","enrollment":103},{"nctId":"NCT02088073","phase":"PHASE3","title":"Safety & Efficacy of Zirconium Silicate Dosed for 28 Days in Hyperkalemia.","status":"COMPLETED","sponsor":"ZS Pharma, Inc.","startDate":"2014-03-31","conditions":"Hyperkalemia","enrollment":258},{"nctId":"NCT02107092","phase":"PHASE3","title":"Open-label Safety & Efficacy of ZS (Sodium Zirconium Cyclosilicate)10g qd to Extend Study ZS-004 in Hyperkalemia.","status":"COMPLETED","sponsor":"ZS Pharma, Inc.","startDate":"2014-05-31","conditions":"Hyperkalemia","enrollment":123},{"nctId":"NCT02163499","phase":"PHASE3","title":"Open-label Safety and Efficacy of Sodium Zirconium Cyclosilicate for up to 12 Months","status":"COMPLETED","sponsor":"ZS Pharma, Inc.","startDate":"2014-06-30","conditions":"Hyperkalemia","enrollment":751},{"nctId":"NCT03283267","phase":"PHASE1","title":"A Safety and Pharmacodynamic Study of Healthy Chinese Subjects Administered Sodium Zirconium Cyclosilicate (ZS)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2017-10-24","conditions":"Hyperkalemia","enrollment":22}],"_emaApprovals":[],"_faersSignals":[{"count":252,"reaction":"DEATH"},{"count":32,"reaction":"BLOOD POTASSIUM INCREASED"},{"count":26,"reaction":"ACUTE KIDNEY INJURY"},{"count":26,"reaction":"VOMITING"},{"count":24,"reaction":"HYPERKALAEMIA"},{"count":23,"reaction":"CHRONIC KIDNEY DISEASE"},{"count":23,"reaction":"RENAL FAILURE"},{"count":22,"reaction":"PNEUMONIA"},{"count":21,"reaction":"END STAGE RENAL DISEASE"},{"count":20,"reaction":"OFF LABEL USE"}],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["ZS"],"phase":"marketed","status":"active","brandName":"Zirconium Cyclosilicate","genericName":"Zirconium Cyclosilicate","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Zirconium cyclosilicate is a non-absorbed potassium binder that traps potassium in the gastrointestinal tract and increases fecal potassium excretion. Used for Hyperkalemia in adults.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}